DBD vs KD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DBD presents a stark dichotomy between explosive earnings growth and concerning sentiment indicators. With a Piotroski F-Score of 4/9, the company's financial health is categorized as stable but lacks strong momentum. While the stock currently trades at a premium to its Graham Number ($42.15) and Intrinsic Value ($74.93), the low forward P/E of 12.75 suggests the market is pricing in continued earnings acceleration. However, heavy insider liquidation and a bearish technical trend significantly offset the strong analyst 'strong_buy' consensus.
Kyndryl presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) but severe valuation and growth headwinds. The current price of $13.46 trades at a significant premium to both its Graham Number ($11.17) and Intrinsic Value ($7.35), suggesting the stock is overvalued despite low P/E and P/S multiples. Financial health is precarious with a high Debt/Equity ratio of 3.04 and a Current Ratio of 0.86, indicating potential liquidity constraints. This is further compounded by a collapse in earnings growth (-71.9% YoY) and a completely bearish technical trend (0/100).
Compare Another Pair
Related Comparisons
DBD vs KD: Head-to-Head Comparison
This page compares Diebold Nixdorf, Incorporated (DBD) and Kyndryl Holdings, Inc. (KD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.